Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiol Therapeutics (CRDL) Total Liabilities (2020 - 2026)

Cardiol Therapeutics filings provide 3 years of Total Liabilities readings, the most recent being $7.2 million for Q4 2022.

  • On a quarterly basis, Total Liabilities fell 21.59% to $7.2 million in Q4 2022 year-over-year; TTM through Dec 2022 was $7.2 million, a 21.59% decrease, with the full-year FY2022 number at $7.2 million, down 21.59% from a year prior.
  • Total Liabilities hit $7.2 million in Q4 2022 for Cardiol Therapeutics, down from $7.4 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $9.2 million in Q4 2021 to a low of $2.0 million in Q4 2020.
  • Median Total Liabilities over the past 3 years was $7.3 million (2022), compared with a mean of $5.9 million.
  • Biggest five-year swings in Total Liabilities: surged 358.92% in 2021 and later dropped 21.59% in 2022.
  • Cardiol Therapeutics' Total Liabilities stood at $2.0 million in 2020, then surged by 358.92% to $9.2 million in 2021, then dropped by 21.59% to $7.2 million in 2022.
  • The last three reported values for Total Liabilities were $7.2 million (Q4 2022), $7.4 million (Q3 2022), and $9.0 million (Q2 2022) per Business Quant data.